Navigation Links
New Clinical Study Shows RyMed InVision-Plus® IV Connector Dramatically Reduced Catheter-Related Bloodstream Infections by Over 92%
Date:2/17/2011

FRANKLIN, Tenn., Feb. 17, 2011 /PRNewswire/ -- Georgia Health Sciences University, Augusta, GA  exhibited a poster at the recent 11th National Conference on Cancer Nursing Research in Los Angeles, in which their clinical study showed RyMed Technologies' zero displacement InVision-Plus® IV Connector significantly decreased the incidence of catheter-related bloodstream infections (CR-BSIs) by 92.6% on average when compared to a simple split septum with negative displacement IV connector (Becton-Dickinson Q-Syte®) and a reversed split-septum device with negative displacement IV connector (ICU Medical Clave®).  No clinical studies have been published comparing different types of connectors in oncology patients on CR-BSIs.  CR-BSIs can cause treatment delays, add time to nursing care, increase costs, increase mortality and decrease quality of life for the patient and family.  

The purpose of the study was to determine infection rates for a split septum valve, a negative reversed split-septum valve and an intraluminal protection device (IPD) with zero displacement in both critical care and medical in-patient oncology patients.  

Detailed results:

  • CR-BSI incidences decreased 96.3%, from 2.9 to 0.1 infections per 1,000 catheter days, when the RyMed InVision-Plus® needleless IV connector was used compared to the Becton-Dickinson's Q-Syte® product.

  • CR-BSI incidences decreased 88.9%, from 3.7 to 0.4 infections per 1,000 catheter days, when the RyMed InVision-Plus® needleless IV connector was used compared to the ICU Medical Clave® product.

  • Overall, 92.6% decrease in infection rate was found when using the RyMed InVision-Plus® with Neutral Advantage™ technology.

  • Leading the study was Dr. Cynthia C. Chernecky PhD, RN, AOCN, FAAN, Jennifer Waller, PhD both from Georgia Health Sciences University; and Denise Macklin, BSN, RNC.  

    Dr. Chernecky stated, "Decreasing infections is essential to quality nursing care in oncology.  The use of best product when added to other nursing interventions is essential as it can enable best outcomes for treatments and ultimately quality of life and a decrease in mortality".

    "This new clinical data continues to demonstrate the superior design features of RyMed's InVision-Plus® needleless IV connector technology and how they have a significant positive patient safety impact among the cancer patient population," said Dana Wm. Ryan, President & CEO, RyMed Technologies, Inc.  

    This poster presentation by Dr. Chernecky was preceded by another in which she highlighted similar success by the RyMed product in decreasing intraluminal thrombotic occlusions compared to a negative displacement mechanical valve.  Additionally, Chernecky also delivered a podium presentation discussing new data on the apparent ineffectiveness of other silver coated needleless IV connectors.

    Catheter-related bloodstream infection (CR-BSI) continues to be one of the most frequent hospital acquired infections (HAIs) reported by hospitals nationwide.  It has been reported that a patient that develops a CR-BSI could die up to 25% of the time, and the industry is discovering that RyMed's InVision-Plus® technology with zero fluid displacement is going to save many lives.

    About RyMed Technologies, Inc.Founded in 1994, RyMed Technologies specializes in the development and marketing of innovative safety products in the field of intravenous catheter care management. The company's products are designed to help reduce catheter-related bloodstream infections (CR-BSIs) and intraluminal thrombotic catheter occlusions associated with needleless IV connectors. More than 10 years of research and development have gone into InVision-Plus® IV Connector.   In January, 2011 the Company introduced the first chlorhexidine/silver ion technology with the new InVision-Plus® CS™.  For more information, call (615) 790-8093 or access www.rymedtech.com. Media Contact: Glen Calder561-750-9800 x216gcalder@transmediagroup.com
    '/>"/>

    SOURCE RyMed Technologies, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
    2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
    3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
    4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
    5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
    6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
    7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
    8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
    9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
    10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
    11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/20/2017)...  Cogentix Medical, Inc. (NASDAQ: CGNT), a global ... Uro/Gyn and Gynecology markets with innovative and proprietary ... the Company as Senior Vice President, Marketing & ... Keswani will report directly to Darin Hammers ... is delighted that Ash has joined the Cogentix ...
    (Date:4/20/2017)... 2017 Research and Markets has ... and Market Prospects: Addressing Production Complexities Through Risk Management ... ... Biosimilar Pipeline and Market Prospects: Overcoming Production Complexities Through ... assessment of the current trends in the global biosimilars ...
    (Date:4/20/2017)... WOONSOCKET, R.I. , April 20, 2017 /PRNewswire/ ... (NYSE: CVS), today unveiled a new store design ... new assortment of healthier food, health-focused products and ... the store to help customers discover new offerings. ... represent the next evolution of the customer experience ...
    Breaking Medicine Technology:
    (Date:4/25/2017)... ... April 25, 2017 , ... Lake Park Dental is now accepting new patients ... in Lutz, FL. With the help of this highly-effective, yet convenient system, patients can ... more discretion and less pain. , Drs. Sarah Jockin, Nicole Morganti, Sara Spear ...
    (Date:4/25/2017)... ... ... Buyers and sellers in the thriving multi-billion dollar cannabis marketplace – from ... be heartened by the industry’s current surge. But another thing that unifies them is ... At last they can simply, safely and effectively end their aroma anguish thanks to ...
    (Date:4/25/2017)... ... April 25, 2017 , ... Vetoquinol USA® ... introducing Flexadin UCII, part of the EQUISTRO line, at this week’s Rolex Kentucky ... horses at the immunologic level. , The scientifically-developed Flexadin UCII supports the body’s ...
    (Date:4/24/2017)... ... April 24, 2017 , ... The Santana Telehealth Project was honored ... 2.0 — the American Telemedicine Association’s annual conference, on April 23 in Orlando, FL. ... telemedicine to improve the lives of the poor and underserved in other parts of ...
    (Date:4/24/2017)... ... ... Bright Pink , a national non-profit organization focusing on the prevention and early detection of ... is proud to announce Katie Thiede as their new Chief Executive Officer. In January, founder ... of the Board and launched a national search to find a visionary new leader to ...
    Breaking Medicine News(10 mins):